A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Emboli

A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Embolization Combined With Dual Immune Checkpoint Inhibitors. is a phase 2, interventional study registered as NCT07333287 by Shandong Provincial Hospital, with a registry enrolment figure of 38 participants, started 2026-02-01 and due to reach its primary completion in 2027-02-28. Interventions recorded: Interventional; Targeted Therapy (anti-VEGF); Immunotherapy + Targeted Therapy; Immunotherapy + Targeted Therapy + Chemotherapy; This cycle is repeated every 21 days.. Conditions listed: Pancreatic Cancer Liver Metastases; Immunotherapy-naive. Primary outcome: Progression-Free Survival（PFS）. Pancreatic eligibility wording from the registry: "Histologically or cytologically confirmed, previously untreated unresectable pancreatic ductal adenocarcinoma with liver metastases (TNM stage: IV)". No results are recorded here; the registry entry is the source.